Arbutus Biopharma Corp Business Combination, Contingent Consideration, Liability, Noncurrent
Arbutus Biopharma Corp (ABUS) had Business Combination, Contingent Consideration, Liability, Noncurrent of $8.82 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent · last filed 2026-08-12
- 2026-06-30: Business Combination, Contingent Consideration, Liability, Noncurrent $8.82M.
- 2026-03-31: Business Combination, Contingent Consideration, Liability, Noncurrent $8.60M.
- 2025-12-31: Business Combination, Contingent Consideration, Liability, Noncurrent $8.39M.
- 2025-09-30: Business Combination, Contingent Consideration, Liability, Noncurrent $11.05M.
| Period end | Business Combination, Contingent Consideration, Liability, Noncurrent | Business Combination, Contingent Consideration, Liability, Noncurrent as first filed |
|---|---|---|
| 2026-06-30 | $8.82M 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $8.60M 10-Q · filed 2026-05-13 | |
| 2025-12-31 | $8.39M 10-Q · filed 2026-08-12 | |
| 2025-09-30 | $11.05M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $10.78M 10-Q · filed 2026-08-12 | |
| 2025-03-31 | $10.52M 10-Q · filed 2026-05-13 | |
| 2024-12-31 | $10.22M 10-Q · filed 2026-08-12 | |
| 2024-09-30 | $8.34M 10-Q · filed 2025-11-13 | |
| 2024-06-30 | $7.99M 10-Q · filed 2025-08-06 | |
| 2024-03-31 | $7.78M 10-Q · filed 2025-05-14 | |
| 2023-12-31 | $7.60M 10-K · filed 2026-03-23 | |
| 2023-09-30 | $7.37M 10-Q · filed 2024-11-06 | |
| 2023-06-30 | $7.17M 10-Q · filed 2024-08-08 | |
| 2023-03-31 | $7.80M 10-Q · filed 2024-05-02 | |
| 2022-12-31 | $7.53M 10-K · filed 2025-03-27 | |
| 2022-09-30 | $5.92M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $5.71M 10-Q · filed 2023-08-03 | |
| 2022-03-31 | $3.63M 10-Q · filed 2023-05-04 | $5.50M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $5.30M 10-K · filed 2024-03-05 | |
| 2021-09-30 | $5.11M 10-Q · filed 2022-11-09 | |
| 2021-06-30 | $4.25M 10-Q · filed 2022-08-04 | |
| 2021-03-31 | $3.56M 10-Q · filed 2022-05-05 | |
| 2020-12-31 | $3.43M 10-K · filed 2023-03-02 | |
| 2020-09-30 | $3.30M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $3.18M 10-Q · filed 2021-08-05 | |
| 2020-03-31 | $3.06M 10-Q · filed 2021-05-05 | |
| 2019-12-31 | $2.95M 10-K · filed 2022-03-03 | |
| 2019-09-30 | $3.00M 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $3.38M 10-Q · filed 2020-08-07 | |
| 2019-03-31 | $3.25M 10-Q · filed 2020-05-11 | |
| 2018-12-31 | $3.13M 10-K · filed 2021-03-04 | |
| 2018-09-30 | $4.16M 10-Q · filed 2019-11-06 | |
| 2018-06-30 | $9.77M 10-Q · filed 2019-08-05 | |
| 2018-03-31 | $9.58M 10-Q · filed 2019-05-06 | |
| 2017-12-31 | $10.42M 10-K · filed 2020-03-05 | |
| 2017-09-30 | $10.21M 10-Q · filed 2018-11-07 | |
| 2017-06-30 | $10.01M 10-Q · filed 2018-08-03 | |
| 2017-03-31 | $10.12M 10-Q · filed 2018-05-04 | |
| 2016-12-31 | $9.06M 10-K · filed 2019-03-07 | |
| 2016-09-30 | $8.25M 10-Q · filed 2017-11-02 | |
| 2016-06-30 | $7.99M 10-Q · filed 2017-08-03 | |
| 2016-03-31 | $7.74M 10-Q · filed 2016-05-04 | |
| 2015-12-31 | $7.50M 10-K · filed 2018-03-16 | |
| 2015-09-30 | $6.67M 10-Q · filed 2015-11-05 | |
| 2015-06-30 | $5.14M 10-Q · filed 2015-08-07 | |
| 2015-03-31 | $4.74M 10-Q · filed 2016-05-04 | |
| 2015-03-04 | $6.73M 10-K · filed 2018-03-16 | |
| 2014-12-31 | $4.74M 10-Q · filed 2016-05-04 | $0.00 10-Q · filed 2015-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |